Rezolute Financials

RZLT Stock  USD 4.99  0.20  4.18%   
Based on the measurements of operating efficiency obtained from Rezolute's historical financial statements, Rezolute is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Rezolute's Non Current Liabilities Total is comparatively stable compared to the past year. Other Stockholder Equity is likely to gain to about 473 M in 2024, whereas Common Stock Total Equity is likely to drop slightly above 34.3 K in 2024. Key indicators impacting Rezolute's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio8.4913.393
Way Down
Slightly volatile
The essential information of the day-to-day investment outlook for Rezolute includes many different criteria found on its balance sheet. An individual investor should monitor Rezolute's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Rezolute.

Net Income

(65.04 Million)

  
Understanding current and past Rezolute Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Rezolute's financial statements are interrelated, with each one affecting the others. For example, an increase in Rezolute's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Rezolute's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Rezolute. Check Rezolute's Beneish M Score to see the likelihood of Rezolute's management manipulating its earnings.

Rezolute Stock Summary

Rezolute competes with Eledon Pharmaceuticals, Clene, and Larimar Therapeutics. Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Rezolute operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 42 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS76200L3096
CUSIP76200L309 037230109 037230208 76200L101
LocationCalifornia; U.S.A
Business Address275 Shoreline Drive,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.rezolutebio.com
Phone650 206 4507
CurrencyUSD - US Dollar

Rezolute Key Financial Ratios

Rezolute Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets11.0M42.6M152.4M123.7M132.7M139.4M
Net Debt(9.5M)(26.6M)(150.2M)(13.6M)(68.2M)(64.8M)
Retained Earnings(147.2M)(168.1M)(209.2M)(261.0M)(329.4M)(313.0M)
Accounts Payable893K1.0M1.1M3.3M4.9M5.1M
Cash10.0M41.0M150.4M16.0M70.4M73.9M
Total Liab3.6M16.5M2.9M7.5M11.7M6.1M
Total Current Assets10.5M42.0M152.1M104.9M128.7M135.1M
Common Stock6K8K34K37K53K49.2K
Other Current Liab2.1M403K1.2M1.4M4.1M4.3M
Other Current Assets563K1.9M1.7M3.0M1.8M1.0M
Short Term Debt245K530K108K541K568K631.7K
Other Liab209K387K407K412K473.8K549.6K
Net Tangible Assets7.4M26.1M149.5M116.2M133.6M140.3M
Other Assets31K191K0.0148K1.00.95
Net Invested Capital7.4M40.1M149.5M116.2M121.0M61.0M
Net Working Capital7.3M40.0M149.6M99.7M119.0M125.0M

Rezolute Key Income Statement Accounts

The reason investors look at the income statement is to determine what Rezolute's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Interest Expense12K375K1.8M919K1.1M1.2M
Gross Profit(18K)(303K)(256K)(382K)(36K)(37.8K)
Operating Income(20.5M)(22.9M)(41.8M)(56.0M)(70.4M)(66.9M)
Ebit(20.3M)(23.2M)(42.1M)(51.8M)(68.5M)(65.0M)
Ebitda(20.3M)(22.9M)(41.8M)(51.4M)(68.4M)(65.0M)
Cost Of Revenue18K303K256K382K36K34.2K
Income Before Tax(20.3M)(20.9M)(41.1M)(51.8M)(68.5M)(65.0M)
Net Income(20.3M)(21.3M)(38.8M)(51.8M)(68.5M)(65.0M)
Income Tax Expense(297.0)375K(2.3M)(137.9K)69.7M73.2M
Research Development14.5M15.0M32.5M43.8M55.7M58.5M
Net Interest Income188K(312K)(1.7M)4.2M4.9M5.1M
Interest Income188K63K80K4.2M4.9M5.1M

Rezolute Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash(1.6M)31.1M109.4M(134.4M)54.4M57.1M
Free Cash Flow(24.2M)(20.4M)(39.6M)(44.6M)(57.4M)(54.5M)
Depreciation49K18K13K30K36K34.2K
Other Non Cash Items222K384K(1.6M)352K595K911.8K
Net Income(20.3M)(20.9M)(41.1M)(51.8M)(68.5M)(65.0M)
End Period Cash Flow10.0M41.0M150.4M16.0M70.4M73.9M
Change To Netincome3.6M2.5M(2.9M)6.3M5.6M3.3M
Investments1.7M231K(101.3M)(101.5M)48.7M51.1M

Rezolute Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Rezolute's current stock value. Our valuation model uses many indicators to compare Rezolute value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rezolute competition to find correlations between indicators driving Rezolute's intrinsic value. More Info.
Rezolute is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers . At this time, Rezolute's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Rezolute by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Rezolute Systematic Risk

Rezolute's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Rezolute volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Rezolute correlated with the market. If Beta is less than 0 Rezolute generally moves in the opposite direction as compared to the market. If Rezolute Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Rezolute is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Rezolute is generally in the same direction as the market. If Beta > 1 Rezolute moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Rezolute Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Rezolute's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Rezolute growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.0972)

At this time, Rezolute's Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Rezolute November 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Rezolute help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Rezolute. We use our internally-developed statistical techniques to arrive at the intrinsic value of Rezolute based on widely used predictive technical indicators. In general, we focus on analyzing Rezolute Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Rezolute's daily price indicators and compare them against related drivers.

Additional Tools for Rezolute Stock Analysis

When running Rezolute's price analysis, check to measure Rezolute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rezolute is operating at the current time. Most of Rezolute's value examination focuses on studying past and present price action to predict the probability of Rezolute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rezolute's price. Additionally, you may evaluate how the addition of Rezolute to your portfolios can decrease your overall portfolio volatility.